Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

作者：Rinki Deo, Manish C. Choudhary, Owen T. Glover, Rachel Bender Ignacio, Julie Boucau, Kara W Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J Giganti, Evgenia Aga, M.R.J. Gibbs, Taylor S. Cohen, Katie Streicher, Karina Soboleva, Courtney V. Fletcher, Eric S. Daar, Alexander L. Greninger, Robert W. Coombs, William A. Fischer, Michael D. Hughes, Davey M. Smith, David A. Wohl, Amy K. Barczak, Jonathan Z. Li · 发表于：Open Forum Infectious Diseases · 年份：2025 · DOI：10.1093/ofid/ofaf542 · 被引用次数：1 · 研究领域：SARS-CoV-2 and COVID-19 Research、CAR-T cell therapy research、Virus-based gene therapy research

We evaluated intramuscular (IM) versus intravenous (IV) administration of tixagevimab/cilgavimab in early COVID-19. Both routes achieved rapid elimination of culturable virus and minimal emergence of resistance. These results support IM delivery as a viable alternative to IV, with important implications for scalable deployment in future viral pandemics.